Monoclonal Antibodies Prove to Be Novel Therapeutics for Myeloma
February 12th 2021
Novel drugs have especially improved the treatment options for relapsed myeloma, with some agents now also being used as frontline therapy. As a result, outcomes for patients with newly diagnosed and relapsed disease continue to improve with prolongation of median survival to greater than 7 years from diagnosis.